Published Date: 04/11/2011
Category: Therapies & Markets
Celgene Corporation - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.Features:Detailed information on Celgene Corporation required for business and competitor intelligence needsA study of the major internal and external factors affecting Celgene Corporation in the form of a SWOT analysisAn in-depth view of the business model of Celgene Corporation including a breakdown and examination of key business segmentsIntelligence on Celgene Corporation’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisorsNews about Celgene Corporation, such as business expansion, restructuring, and contract winsLarge number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to Purchase: Gain understanding of Celgene Corporation and the factors that influence its strategies Track strategic initiatives of the company and latest corporate news and actions Assess Celgene Corporation as a prospective partner, vendor or supplierSupport sales activities by understanding your customers' businesses better Stay up to date on Celgene Corporation’s business structure, strategy and prospects
Celgene Corporation
Celgene, an integrated biopharmaceutical company, discovers, develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The company primarily operates in the US. The company is headquartered in Summit, New Jersey and employed 4,182 people as of December 31, 2010. The company recorded revenues of $3,625.7 million during the financial year (FY) ended December 2010, an increase of 34.8% over FY2009. The operating profit of the company was $989.6 million during FY2010, an increase of 17.6% over FY2009. The net profit was $880.5 million in FY2010, an increase of 13.4% over FY2009.